Trial · NCT00161473
Alzheimer's in Long-Term Care--Treatment for Agitation
NCT00161473, Not applicable, Completed, University of Washington; results first posted 2012-08-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alzheimer's in Long-Term Care--Treatment for Agitation. Trials, record NCT00161473. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00161473
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alzheimer's in Long-Term Care--Treatment for Agitation
- NCT number
- NCT00161473
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- University of Washington
- Conditions
- Alzheimer Disease, Psychomotor Agitation
- Interventions
- prazosin, placebo (inert substance)
- First posted
- 2005-09-12
- Last updated
- 2012-08-02
- Results first posted
- 2012-08-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Clinical Global Impression of Change (CGIC) at Last Observation | Week 8 | The Clinical Global Impression of Change (CGIC) is a 7 point scale, where 1 indicates "markedly improved," 4 indicates "no change," and 7 indicates "markedly worse." |
| Primary | Change in Neuropsychiatric Inventory (NPI) Total Score Over the Course of Study Participation | Weeks 2, 4, 6, and 8 (change from Baseline) | The Neuropsychiatric Inventory (NPI) is a 12-item scale that assesses the frequency and severity of behavioral symptoms in patients with dementia. Each Neuropsychiatric Inventory item ranges from 0 to 12. Therefore the Neuropsychiatric Inventory total score has a minimum total value of 0 and maximum 144, where 144 indicates higher levels of behavioral symptoms. A change in Neuropsychiatric Inventory total score that is a negative number (that is, an Neuropsychiatric Inventory score decrease), indicates behavioral improvement. |
| Secondary | Number of Behavioral Assessment Visits Completed | Last behavioral assessment (Baseline, Weeks 1, 2, 4, 6, or 8) | This measure reflects the length of time participants remained in the study. There were 6 behavioral assessment visits included in the protocol. |
| Secondary | Change in Brief Psychiatric Rating Scale (BPRS) Total Score Over the Course of Study Participation | Weeks 2, 4, 6, and 8 (change from Baseline) | The Brief Psychiatric Rating Scale (BPRS) is an 18-item scale that rates psychiatric symptoms. Each item ranges from 1 to 7. Therefore, the Brief Psychiatric Rating Scale total score ranges from a minimum of 0 to a maximum of 126, where 126 indicates higher levels of behavioral symptoms. A change Brief Psychiatric Rating Scale score that is a negative number (that is, a Brief Psychiatric Rating Scale score decrease), indicates behavioral improvement. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Clinical Global Impression of Change (CGIC) at Last Observation | Week 8 | Participants with at least one follow-up behavioral assessment visit were included in this analysis | units on a scale | MEAN |
| PRIMARY | Change in Neuropsychiatric Inventory (NPI) Total Score Over the Course of Study Participation | Weeks 2, 4, 6, and 8 (change from Baseline) | Participants with at least one follow-up behavioral assessment visit were included in this analysis.~The mean group change was calculated by calculating the mean of each participant's follow-up measures, subtracting this mean from the baseline value, and then from these values, calculating group means and standard deviations. | units on a scale | MEAN |
| SECONDARY | Number of Behavioral Assessment Visits Completed | Last behavioral assessment (Baseline, Weeks 1, 2, 4, 6, or 8) | number of visits | MEAN | |
| SECONDARY | Change in Brief Psychiatric Rating Scale (BPRS) Total Score Over the Course of Study Participation | Weeks 2, 4, 6, and 8 (change from Baseline) | Participants with at least one follow-up behavioral assessment visit were included in this analysis.~The mean group change was determined by calculating the mean of each participant's follow-up measures, subtracting this mean from the baseline value, and then from these values, calculating group means and standard deviations. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Clinical Global Impression of Change (CGIC) at Last Observation | Prazosin | 2.6 | Standard Deviation 1.0 | units on a scale | |
| Mean Clinical Global Impression of Change (CGIC) at Last Observation | Placebo | 4.5 | Standard Deviation 1.6 | units on a scale | |
| Change in Neuropsychiatric Inventory (NPI) Total Score Over the Course of Study Participation | Prazosin | -19 | Standard Deviation 21 | units on a scale | |
| Change in Neuropsychiatric Inventory (NPI) Total Score Over the Course of Study Participation | Placebo | -2 | Standard Deviation 15 | units on a scale | |
| Number of Behavioral Assessment Visits Completed | Prazosin | 4.8 | Standard Deviation 1.6 | number of visits | |
| Number of Behavioral Assessment Visits Completed | Placebo | 4.5 | Standard Deviation 1.8 | number of visits | |
| Change in Brief Psychiatric Rating Scale (BPRS) Total Score Over the Course of Study Participation | Prazosin | -9 | Standard Deviation 9 | units on a scale | |
| Change in Brief Psychiatric Rating Scale (BPRS) Total Score Over the Course of Study Participation | Placebo | -3 | Standard Deviation 5 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prazosin | 12 | |
| Overall Study | STARTED | Placebo | 12 | |
| Overall Study | COMPLETED | Prazosin | 7 | |
| Overall Study | COMPLETED | Placebo | 6 | |
| Overall Study | NOT COMPLETED | Prazosin | 5 | |
| Overall Study | NOT COMPLETED | Placebo | 6 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | sedation | Nervous system disorders | Prazosin | 3 | 12 | 3 |
| other | sedation | Nervous system disorders | Placebo | 3 | 12 | 3 |
| other | confusion | Nervous system disorders | Prazosin | 1 | 12 | 1 |
| other | confusion | Nervous system disorders | Placebo | 4 | 12 | 4 |
| other | lower extremity edema | Vascular disorders | Prazosin | 1 | 12 | 1 |
| other | lower extremity edema | Vascular disorders | Placebo | 2 | 12 | 2 |
| other | hypotension | Vascular disorders | Prazosin | 2 | 12 | 2 |
| other | hypotension | Vascular disorders | Placebo | 1 | 12 | 1 |
| other | headache | Nervous system disorders | Prazosin | 0 | 12 | 0 |
| other | headache | Nervous system disorders | Placebo | 2 | 12 | 2 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prazosin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Prazosin | 6 | 12 |
| Total, other adverse events | Placebo | 9 | 12 |
| Total, serious adverse events | Prazosin | 0 | 12 |
| Total, serious adverse events | Placebo | 0 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 19700947 | RESULT |
Source PubMed
Grants2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| P50AG005136 | Alzheimer's Disease Research Center | GRABOWSKI, THOMAS J. | UNIVERSITY OF WASHINGTON | NATIONAL INSTITUTE ON AGING | 1985 to 2019 | NIH RePORTER |
| R01AG018644 | ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION | PESKIND, ELAINE R. | UNIVERSITY OF WASHINGTON | NATIONAL INSTITUTE ON AGING | 2000 to 2003 | NIH RePORTER |
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Prazosin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00161473
GET https://conductscience.org/api/trials/v1/NCT00161473/registered